Triptorelin (GnRH) – 2MG

Triptorelin (GnRH)

Scientists believe that gonadotropin-releasing hormones (GnRH) are secreted by the hypothalamus and trigger the production and secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). When GnRH pulsatility gets disturbed, fertility seems to be affected as well, which is probably attributed to excessive malnutrition of aging and other reproductive dysfunctions.

It is a decapeptide, which means that it eight more amino acids than natural GnRH and the phosphatomimetic group. Triptorelin: (1) Triptorelin is a gonadotrophin hormone-releasing factor analogue that reduces the secretion of LH and FSH; and (2) The synthetic decapeptide triptorelin acetate stimulates the pituitary gland, as seen on your MRI check-up to synthesize and release both LH and FSH.

Researchers speculate that an agonist analog of gonadotropin releasing hormone (GnRH), like Triptorelin might bind to receptors in the pituitary gland and thereby stimulate the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This could possibly make an initial increase in the secretion of LH and FSH during the first phase This might later result in some downregulation of their receptors, causing decreased release of LH and FSH.

A decrease in levels of the LH and FSH hormones dampens testosterone and estrogen levels, say scientists-androgen and estrogen are types of sex hormone. This event could result in down regulation of steroidogenesis of the ovary and testis. Researchers also recommend that this drug may have some role in maintaining a decrease in secretion of LH and FSH.

In this randomized phase III clinical trial, 1,065 premenopausal female test subjects with early breast cancer were recruited. Triptorelin was administered for 5 years to all candidates, in combination with either Tamoxifen or Letrozole/Zoledronic acid. Sixty-four months and analysis after follow-up, the disease-free rate in those subjects was 85 percent, and 93.2 percent and 93.3 percent of subjects co-presented with Tamoxifen, Letrozole or Zoledronic acid respectively.

Prostate, a small gland in the male reproductive system that produces and transports seminal fluid to the sperm. One approach through which scientists are tacking down prostate cancer cell de-activation is that of depriving androgen production. Scientists speculate that by doing this it has a seriously revocable effect on plasma testosterone levels. In one clinical study, a retrospective analysis comparing the effect of 1, 3 and 6-month administration of the Triptorelin peptide was performed. Of the 920 males with prostate cancer recruited in this study. The testosterone levels were quan- titatively determined at 1, 3, 6, 9 and 12 months after peptide presentation. After analyzing: 80%, 92%,93%,92% and 91%(respectively) of subjects showed decrease in plasma testosterone.

THE CONTENT ON THIS WEBSITE IS STRICTLY INFORMATIONAL. IT IS NOT INTENDED TO BE TAKEN AS MEDICAL ADVICE OR AS A SCIENTIFIC PUBLICATION.

None of the products have been evaluated by The Food and Drug Administration, and are not for medical use. Their use in human or animal subjects is strictly prohibited by law, and they are available here only for in-vitro research purposes, by licensed professionals. By purchasing from this site, you agree to comply with our Terms and Conditions.